Bionik Laboratories (BNKL) vs. Edwards Lifesciences (EW) Financial Contrast

Bionik Laboratories (OTCMKTS:BNKL) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Risk and Volatility

Bionik Laboratories has a beta of -1.18, indicating that its stock price is 218% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.


This table compares Bionik Laboratories and Edwards Lifesciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bionik Laboratories -782.97% -69.15% -53.86%
Edwards Lifesciences 20.67% 30.11% 16.54%

Institutional & Insider Ownership

82.3% of Edwards Lifesciences shares are held by institutional investors. 45.0% of Bionik Laboratories shares are held by company insiders. Comparatively, 1.8% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Bionik Laboratories and Edwards Lifesciences’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bionik Laboratories $990,000.00 18.82 -$14.62 million N/A N/A
Edwards Lifesciences $3.44 billion 9.30 $583.60 million $3.80 40.21

Edwards Lifesciences has higher revenue and earnings than Bionik Laboratories.

Analyst Recommendations

This is a breakdown of current recommendations for Bionik Laboratories and Edwards Lifesciences, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bionik Laboratories 0 0 0 0 N/A
Edwards Lifesciences 2 7 12 0 2.48

Edwards Lifesciences has a consensus price target of $164.25, suggesting a potential upside of 7.49%. Given Edwards Lifesciences’ higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Bionik Laboratories.


Edwards Lifesciences beats Bionik Laboratories on 9 of the 11 factors compared between the two stocks.

Bionik Laboratories Company Profile

Bionik Laboratories Corp., a robotics company, focuses on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The company specializes in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Systems, which include the InMotion ARM that allows clinicians to deliver sensor motor therapy to the shoulder and elbow to develop new neural pathways; InMotion ARM/HAND, an add-on module to be used with the InMotion ARM; and InMotion WRIST, a rehabilitation device that enables clinicians to deliver optimum intensive sensor motor wrist and forearm therapy to patients with neurological conditions. The company is also developing InMotion HOME, an upper extremity product that allows patients to extend their therapy for as long as needed while rehabilitating at home; and ARKE, a robotic lower body exoskeleton designed for wheelchair bound individuals suffering from spinal cord injuries, stroke, and other mobility disabilities. Bionik Laboratories Corp. was founded in 2010 and is headquartered in Toronto, Canada.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

Receive News & Ratings for Bionik Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionik Laboratories and related companies with's FREE daily email newsletter.

Leave a Reply